{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T14:28:09Z","timestamp":1744986489598,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Sofosbuvir\/Velpatasvir (Epclusa, ECS) is the first pan-genotype direct-acting antiviral agent (DAA) for hepatitis C virus (HCV) infection, and Danoprevir (DNV) is the first DAA developed by a Chinese local enterprise, which is suitable for combined use with other drugs to treat genotype 1b chronic hepatitis C. However, previous reports have never compared the real-world data of ECS and DNV.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients and methods<\/jats:title>\n                <jats:p>178 chronic hepatitis C patients were retrospectively recruited, and 94cases were accepted with Sofosbuvir\/Velpatasvir\u2009\u00b1\u2009Ribavirin (ECS group), and others (<jats:italic>n<\/jats:italic>\u2009=\u200984 treated with DNV combination therapy (DNV group). The HCV genotype, virological response, adverse effects and some laboratory biochemical indexes were contrasted between above two groups in the real world study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>DNV group had significantly lower level of alpha-fetoprotein (AFP), lower rates of decompensated cirrhosis ( <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). ECS group possessed more 6a (31.91% vs.13.10%) while DNV group was provided with more 1b (48.81% vs. 22.34%) patients. Significantly poor liver function was detected in ECS group at 4-week treatment (ALT and AST) and 12-week follow-up (AST) (all <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). The SVR12 undetectable rates of both groups were 100%, and no serious event was observed during the treatment and follow-up in both groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In this retrospective real-world study, the efficacy of DNV combined therapy is similar to Sofosbuvir\/Velpatasvir\u2009\u00b1\u2009Ribavirin for chronic HCV infection, and the safety is comparable. DNV based therapy is a promising regimen for chronic hepatitis C.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-024-03147-5","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T14:02:39Z","timestamp":1707919359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative efficacy and safety of Sofosbuvir\/Velpatasvir and Danoprevir for the treatment of chronic hepatitis C: the real-world data in China"],"prefix":"10.1186","volume":"24","author":[{"given":"Yunjing","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minfeng","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiting","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honglian","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingzi","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1305-2267","authenticated-orcid":false,"given":"Chaoshuang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,14]]},"reference":[{"issue":"10","key":"3147_CR1","first-page":"664","volume":"95","author":"U.S. FOOD & DRUG","year":"2017","unstructured":"U.S. FOOD & DRUG. FDA approves Epclusa for treatment of chronic Hepatitis C virus infection. FDA news release.","journal-title":"Am Fam Physician"},{"key":"3147_CR2","unstructured":"Sokol R. Sofosbuvir\/Velpatasvir (Epclusa) for Hepatitis C. Am Fam Physician. 2017 May 15;95(10):664\u2013666. pii: d13301. PubMed PMID: 28671408."},{"key":"3147_CR3","doi-asserted-by":"publisher","unstructured":"Markham A, Keam SJ, Danoprevir. First Global Approval. Drugs. 2018;78(12):1271\u20131276. pii: https:\/\/doi.org\/10.1007\/s40265-018-0960-0. https:\/\/doi.org\/10.1007\/s40265-018-0960-0. PubMed PMID: 30117020.","DOI":"10.1007\/s40265-018-0960-0 10.1007\/s40265-018-0960-0"},{"issue":"5","key":"3147_CR4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s11904-019-00466-1","volume":"16","author":"A Mohanty","year":"2019","unstructured":"Mohanty A, Salameh S, Butt AA. Impact of direct acting Antiviral Agent Therapy upon Extrahepatic manifestations of Hepatitis C virus infection. Curr HIV\/AIDS Rep. 2019;16(5):389\u201394. https:\/\/doi.org\/10.1007\/s11904-019-00466-1. PubMed PMID: 31482299.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"4","key":"3147_CR5","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.annonc.2021.12.015","volume":"33","author":"PS Mishra-Kalyani","year":"2022","unstructured":"Mishra-Kalyani PS, Amiri Kordestani L, Rivera DR, Singh H, Ibrahim A, DeClaro RA, Shen Y, Tang S, Sridhara R, Kluetz PG, Concato J, Pazdur R, Beaver JA. External control arms in oncology: current use and future directions. Ann Oncol. 2022;33(4):376\u201383. https:\/\/doi.org\/10.1016\/j.annonc.2021.12.015. PubMed PMID: 35026413.","journal-title":"Ann Oncol"},{"key":"3147_CR6","doi-asserted-by":"publisher","unstructured":"Johnson P, Zhou Q, Dao DY, Lo YMD. Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2022 Jun 8. pii: https:\/\/doi.org\/10.1038\/s41575-022-00620-y. https:\/\/doi.org\/10.1038\/s41575-022-00620-y. PubMed PMID: 35676420.","DOI":"10.1038\/s41575-022-00620-y 10.1038\/s41575-022-00620-y"},{"key":"3147_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cca.2016.10.006","volume":"463","author":"C Sauzay","year":"2016","unstructured":"Sauzay C, Petit A, Bourgeois AM, Barbare JC, Chauffert B, Galmiche A, Houessinon A. Alpha-foetoprotein (AFP): a multi-purpose marker in hepatocellular carcinoma. Clin Chim Acta. 2016;463:39\u201344. https:\/\/doi.org\/10.1016\/j.cca.2016.10.006. PubMed PMID: 27732875.","journal-title":"Clin Chim Acta"},{"key":"3147_CR8","doi-asserted-by":"publisher","first-page":"635476","DOI":"10.3389\/fcell.2021.635476","volume":"9","author":"B Lin","year":"2021","unstructured":"Lin B, Dong X, Wang Q, Li W, Zhu M, Li M. AFP-Inhibiting fragments for drug delivery: the Promise and challenges of Targeting therapeutics to cancers. Front Cell Dev Biol. 2021;9:635476. https:\/\/doi.org\/10.3389\/fcell.2021.635476. PubMed PMID: 33898423.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"3147_CR9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2174\/1871526518666180816101124","volume":"20","author":"D Chopra","year":"2020","unstructured":"Chopra D, Bhandari B, Sofosbuvir. Really meets the Unmet needs for Hepatitis C treatment? Infect Disord Drug Targets. 2020;20(1):2\u201315. pii: IDDT-EPUB-92411. https:\/\/doi.org\/10.2174\/1871526518666180816101124. PubMed PMID: 30113002.","journal-title":"Infect Disord Drug Targets"},{"key":"3147_CR10","doi-asserted-by":"publisher","unstructured":"Heo YA, Deeks ED. Sofosbuvir\/Velpatasvir\/Voxilaprevir: A Review in Chronic Hepatitis C. Drugs. 2018;78(5):577\u2013587. pii: https:\/\/doi.org\/10.1007\/s40265-018-0895-5. doi: 10.1007\/s40265-018-0895-5. PubMed PMID: 29546556.","DOI":"10.1007\/s40265-018-0895-5"},{"key":"3147_CR11","doi-asserted-by":"publisher","unstructured":"Pan S, Feng K, Huang P, Zeng Y, Ke L, Yang X, Liu J, Lin C. Efficacy and safety of danoprevir plus sofosbuvir in GT 1, 2, 3, or 6 chronic hepatitis C patients with or without cirrhosis in China. Medicine (Baltimore). 2021;100(24):e26312. pii: 00005792-202106180-00030. https:\/\/doi.org\/10.1097\/MD.0000000000026312. PubMed PMID: 34128871.","DOI":"10.1097\/MD.0000000000026312"},{"issue":"11","key":"3147_CR12","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1038\/emi.2017.77","volume":"6","author":"Y Chen","year":"2017","unstructured":"Chen Y, Yu C, Yin X, Guo X, Wu S, Hou J. Hepatitis C virus genotypes and subtypes circulating in Mainland China. Emerg Microbes Infections. 2017;6(11):e95. https:\/\/doi.org\/10.1038\/emi.2017.77.","journal-title":"Emerg Microbes Infections"},{"issue":"5","key":"3147_CR13","doi-asserted-by":"publisher","first-page":"4285","DOI":"10.3892\/mmr.2016.5737","volume":"14","author":"X Shao","year":"2016","unstructured":"Shao X, Luo Q, Cai Q, Zhang F, Zhu J, Liu Y, Zhao Z, Gao Z, Zhang X. An outbreak of HCV genotype 6a and 2a infection in South China: confirmation of iatrogenic transmission by phylogenetic analysis of the NS5B region. Mol Med Rep. 2016;14(5):4285\u201392. https:\/\/doi.org\/10.3892\/mmr.2016.5737. PubMed PMID: 27633350.","journal-title":"Mol Med Rep"},{"key":"3147_CR14","doi-asserted-by":"publisher","first-page":"9849823","DOI":"10.1155\/2017\/9849823","volume":"2017","author":"Z Li","year":"2017","unstructured":"Li Z, Liu Y, Zhang Y, Shao X, Luo Q, Guo X, Lin G, Cai Q, Zhao Z, Chong Y. Naturally Occurring Resistance-Associated variants to Hepatitis C Virus Direct-acting antiviral agents in treatment-naive HCV genotype 6a-Infected patients. Biomed Res Int. 2017;2017:9849823. https:\/\/doi.org\/10.1155\/2017\/9849823. PubMed PMID: 29164151.","journal-title":"Biomed Res Int"},{"issue":"6","key":"3147_CR15","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1001\/jama.2016.12279","volume":"317","author":"Sofosbuvir\/Velpatasvir","year":"2017","unstructured":"Sofosbuvir\/Velpatasvir. (Epclusa) for Hepatitis C. JAMA. 2017;317(6):639\u201340. pii: 2601498. https:\/\/doi.org\/10.1001\/jama.2016.12279. PubMed PMID: 28196252.","journal-title":"JAMA"},{"issue":"27","key":"3147_CR16","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","volume":"373","author":"JJ Feld","year":"2015","unstructured":"Feld JJ, Jacobson IM, H\u00e9zode C, Asselah T, Ruane PJ, Gruener N, Abergel A, Mangia A, Lai CL, Chan HL, Mazzotta F, Moreno C, Yoshida E, Shafran SD, Towner WJ, Tran TT, McNally J, Osinusi A, Svarovskaia E, Zhu Y, Brainard DM, McHutchison JG, Agarwal K, Zeuzem S. ASTRAL-1 investigators. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373(27):2599\u2013607. https:\/\/doi.org\/10.1056\/NEJMoa1512610. PubMed PMID: 26571066.","journal-title":"N Engl J Med"},{"issue":"27","key":"3147_CR17","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","volume":"373","author":"MP Curry","year":"2015","unstructured":"Curry MP, O\u2019Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, Reddy KR, Lawitz E, Flamm SL, Schiano T, Teperman L, Fontana R, Schiff E, Fried M, Doehle B, An D, McNally J, Osinusi A, Brainard DM, McHutchison JG, Brown RS, Charlton M. ASTRAL-4 investigators. Sofosbuvir and Velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373(27):2618\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1512614. PubMed PMID: 26569658.","journal-title":"N Engl J Med"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03147-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-024-03147-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03147-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T14:07:11Z","timestamp":1707919631000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-024-03147-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,14]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3147"],"URL":"https:\/\/doi.org\/10.1186\/s12876-024-03147-5","relation":{},"ISSN":["1471-230X"],"issn-type":[{"type":"electronic","value":"1471-230X"}],"subject":[],"published":{"date-parts":[[2024,2,14]]},"assertion":[{"value":"5 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors are accountable for all aspects of the work, including ensuring that any questions related to the accuracy or integrity of any part of the work have been appropriately investigated and resolved. All patients who participated in this study signed an informed consent form, and this study was approved by institutional ethics board of The Third Affiliated Hospital of Sun Yat-Sen University (No. [2022]02-272-01). All procedures performed in this study involving human participants were in accordance with the Declaration of Helsinki (as revised in 2013).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}